- Home
- DLR vs TAK Comparison
DLR vs TAK Comparison
Compare DLR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLR | TAK |
|---|---|---|
| Founded | 2004 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.6B | 59.8B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DLR | TAK |
|---|---|---|
| Price | $183.79 | $21.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 34 | 3 |
| Target Price | ★ $224.22 | $23.00 |
| AVG Volume (30 Days) | 2.1M | ★ 2.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.71% | 2.37% |
| EPS Growth | ★ 122.36 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $6,112,692,000.00 | N/A |
| Revenue This Year | $20.01 | $4.46 |
| Revenue Next Year | $11.13 | $2.11 |
| P/E Ratio | $390.30 | ★ $41.25 |
| Revenue Growth | ★ 10.04 | N/A |
| 52 Week Low | $146.23 | $13.56 |
| 52 Week High | $208.14 | $21.22 |
Technical Indicators
Market Signals| Indicator | DLR | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 68.41 |
| Support Level | $179.08 | $17.73 |
| Resistance Level | $184.62 | N/A |
| Average True Range (ATR) | 5.06 | 0.32 |
| MACD | 0.85 | 0.08 |
| Stochastic Oscillator | 69.24 | 73.45 |
Price Performance
Historical ComparisonAbout DLR Digital Realty Trust Inc.
Digital Realty is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and large businesses. Digital Realty operates 300 properties in 57 metropolitan areas across 31 countries, serving 5,000 customers. Renting physical space accounts for about 90% of Digital Realty's revenue. The firm enables hyperscalers and other clients to store servers, data, and networking equipment. The other 10% of revenue is generated primarily through interconnection services (8%) and other fee income (2%).
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.